Intradermal, low dose, short course hepatitis B vaccination.
Seventy-five of 88 (85.2%) vaccinees seroconverted at three months after three 2 micrograms doses of a plasma-derived hepatitis B vaccine had been given intradermally one month apart. Vaccinees under 30 years of age had a significantly better seroconversion rate (88.8%) than older subjects (50%) as measured at three months. Forty-three of 47 (91%) vaccinees who were bled one year post vaccination had antibody levels in excess of 10 IU/1. This study indicates that short course, low dose, intradermal vaccination with plasma-derived hepatitis B vaccine may be a viable and cheap regimen for inducing immunity against hepatitis B in younger subjects.
D000279:Administration, Cutaneous; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines